LivingGLP1
Study S002468

Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes: A Target Trial Emulation

ClinicalTrials.gov recordStudy Protocol and Statistical Analysis Plan (PDF)

Registration

Registration
NCT07513259
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
203424
Start
2018-01-01
Primary completion
2025-10-31
Lead sponsor
Chung Shan Medical University
Conditions
Obesity & Overweight; Diabetes Mellitus Type 2; Neoplasms
Results posted
TRUE
Individual participant data sharing
NO

Registered primary outcomes

  • All-cause Mortality (Comparison 1) [From obesity-associated cancer diagnosis through 36 months]
  • All-cause Mortality (Comparison 2) [From obesity-associated cancer diagnosis through 36 months]
  • All-cause Mortality (Comparison 3) [From obesity-associated cancer diagnosis through 36 months]
  • All-cause Mortality (Comparison 4) [From obesity-associated cancer diagnosis through 36 months]
  • All-cause Mortality (Comparison 5) [From obesity-associated cancer diagnosis through 36 months]

Linked records (17)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0001420Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.
Ko A, Annals of internal medicine
2026Systematic reviewPMID 41359966DOIregistry reference BACKGROUND:41359966
R0002537Effectiveness of Pre-Transplant Dual GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy on All-Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target-Trial Emulation.
Huang YN, Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026Nonrandomized studyPMID 41387113DOIregistry reference BACKGROUND:41387113
R0002551GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation.
Chan SH, Diabetes research and clinical practice
2026Nonrandomized studyPMID 41453566DOIregistry reference BACKGROUND:41453566
R0002718Information pharmacists assist in the construction of GLP-1RA prescription review rules in a tertiary hospital in China.
Zhou L, BMC health services research
2025Nonrandomized studyPMID 41034888DOIregistry reference BACKGROUND:41034888
R0002951GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.
Dai H, JAMA oncology
2025Nonrandomized studyPMID 40839273DOIregistry reference BACKGROUND:40839273
R0003397Repurposing glucose-lowering drugs for cancer therapy.
Luconi M, Trends in cancer
2025PreclinicalPMID 40374399DOIregistry reference BACKGROUND:40374399
R0006091GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.
Silverii GA, Diabetes, obesity & metabolism
2025Systematic reviewPMID 40437949DOIregistry reference BACKGROUND:40437949
R0007685GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research.
Valencia-Rincón E, The Journal of clinical investigation
2025Narrative reviewPMID 41178720DOIregistry reference BACKGROUND:41178720
R0010422Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers.
Kim C, JAMA oncology
2025Nonrandomized studyPMID 41196576DOIregistry reference BACKGROUND:41196576
R0016105GLP-1-based therapies for diabetes, obesity and beyond.
Drucker DJ, Nature reviews. Drug discovery
2025Narrative reviewPMID 40281304DOIregistry reference BACKGROUND:40281304
R0029579Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.
Wong CK, The Journal of clinical investigation
2025PreclinicalPMID 41178710DOIregistry reference BACKGROUND:41178710
R0003638Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
Huang YN, Diabetes, obesity & metabolism
2024Nonrandomized studyPMID 39171569DOIregistry reference BACKGROUND:39171569
R0005924Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation.
Wong CK, Cell metabolism
2024OtherPMID 38113888DOIregistry reference BACKGROUND:38113888
R0006897Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.
Wang L, JAMA network open
2024Nonrandomized studyPMID 38967919DOIregistry reference BACKGROUND:38967919
R0011025Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.
Zheng Z, Signal transduction and targeted therapy
2024Other trialPMID 39289339DOIregistry reference BACKGROUND:39289339
R0016510GLP-1 programs the neurovascular landscape.
Chen B, Cell metabolism
2024Narrative reviewPMID 39357509DOIregistry reference BACKGROUND:39357509
R0019647Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, The New England journal of medicine
2024Randomized trialPMID 38785209DOIregistry reference BACKGROUND:38785209